Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Type (Seasonal and Pandemic), Technology (Egg-based and Cell-based), Age Group (Pediatric and Adult), and Route of Administration (Injection and Nasal Spray): Global Opportunity Analysis and Industry Forecast, 2019-2026
The global influenza vaccine market was valued at $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026.
Influenza, commonly known as flu, is a contagious respiratory infection caused by influenza viruses. Four types of influenza viruses include type A, B, C, and D. The most common types of influenza viruses responsible for seasonal flu each year are type A and B. These viruses enter into the respiratory system of an individual, and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The ideal method to prevent influenza is through vaccination.
The key factors that drive the growth of the global influenza vaccine market include increase in government initiatives to ensure well-being of population, minimal side effects associated with influenza vaccines, advancements in existing vaccines, and development of new vaccines. In addition, upsurge in funding and investments by companies in R&D activities supplements the growth of this market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. Conversely, routine immunization programs in developed and developing countries are expected to provide lucrative opportunities for market expansion.
The global influenza vaccines market is segmented into vaccine type, type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. Depending on type, it is segregated into seasonal and pandemic. As per technology, it is classified into egg-based and cell-based. According to age group, it is divided into pediatric and adult. On the basis of route of administration, it is categorized into injection and nasal spray. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
Influenza, commonly known as flu, is a contagious respiratory infection caused by influenza viruses. Four types of influenza viruses include type A, B, C, and D. The most common types of influenza viruses responsible for seasonal flu each year are type A and B. These viruses enter into the respiratory system of an individual, and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The ideal method to prevent influenza is through vaccination.
The key factors that drive the growth of the global influenza vaccine market include increase in government initiatives to ensure well-being of population, minimal side effects associated with influenza vaccines, advancements in existing vaccines, and development of new vaccines. In addition, upsurge in funding and investments by companies in R&D activities supplements the growth of this market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. Conversely, routine immunization programs in developed and developing countries are expected to provide lucrative opportunities for market expansion.
The global influenza vaccines market is segmented into vaccine type, type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. Depending on type, it is segregated into seasonal and pandemic. As per technology, it is classified into egg-based and cell-based. According to age group, it is divided into pediatric and adult. On the basis of route of administration, it is categorized into injection and nasal spray. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global influenza vaccine market is provided.
- An extensive analysis of various regions provides insights that allows companies to strategically plan their business moves.
- By Vaccine type
- Quadrivalent
- Trivalent
- By Type
- Seasonal
- Pandemic
- By Technology
- Egg-based
- Cell-based
- By Age Group
- Pediatric
- Adult
- By Route of Administration
- Injection
- Nasal Spray
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- AstraZeneca Plc.
- Biodiem
- CSL Limited
- Emergent BioSolutions
- F. Hoffmann-La Roche Ltd.
- Gamma Vaccines Pty Ltd.
- GlaxoSmithKline Plc.
- Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
- Novartis AG
- Pfizer, Inc.
- Sanofi Pasteur SA
- Sinovac Biotech Ltd.
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key Findings of The Study
2.2. Cxo Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter'S Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. High Prevalence of Influenza
3.4.1.2. Increase In Government Focus On Immunization Programs
3.4.1.3. Emerging Vaccines
3.4.1.4. Technological Progress In Vaccine Administration
3.4.2. Restraints
3.4.2.1. Longer Timelines And Implementation of Stringent Regulations
3.4.2.2. High Costs Associated With The Development of Vaccines
3.4.3. Opportunity
3.4.3.1. High Growth Prospects In Emerging Markets
CHAPTER 4: INFLUENZA VACCINE MARKET, BY VACCINE TYPE
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Quadrivalent
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Trivalent
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
CHAPTER 5: INFLUENZA VACCINE MARKET, BY TYPE
5.1. Overview
5.2. Seasonal Influenza Vaccine
5.3. Pandemic Influenza Vaccine
CHAPTER 6: INFLUENZA VACCINE MARKET, BY TECHNOLOGY
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Egg-Based
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Cell Culture
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
CHAPTER 7: INFLUENZA VACCINE MARKET, BY AGE GROUP
7.1. Overview
7.1.1. Market Size And Forecast
7.2. Pediatric
7.2.1. Market Size And Forecast, By Region
7.2.2. Market Analysis, By Country
7.3. Adult
7.3.1. Market Size And Forecast, By Region
7.3.2. Market Analysis, By Country
CHAPTER 8: INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION
8.1. Overview
8.1.1. Market Size And Forecast
8.2. Injection
8.2.1. Market Size And Forecast
8.2.2. Market Analysis, By Country
8.3. Nasal Spray
8.3.1. Market Size And Forecast
8.3.2. Market Analysis, By Country
CHAPTER 9: GLOBAL INFLUENZA VACCINE MARKET, BY REGION
9.1. Overview
9.1.1. Market Size And Forecast
9.2. North America
9.2.1. Key Market Trends And Opportunities
9.2.2. Market Size And Forecast, By Vaccine Type
9.2.3. Market Size And Forecast, By Technology
9.2.4. Market Size And Forecast, By Age Group
9.2.5. Market Size And Forecast, By Route of Administration
9.2.6. Market Size And Forecast, By Country
9.2.6.1. U.S. Market Size And Forecast, By Vaccine Type
9.2.6.2. U.S. Market Size And Forecast, By Technology
9.2.6.3. U.S. Market Size And Forecast, By Age Group
9.2.6.4. U.S. Market Size And Forecast, By Route of Administration
9.2.6.5. Canada Market Size And Forecast, By Vaccine Type
9.2.6.6. Canada Market Size And Forecast, By Technology
9.2.6.7. Canada Market Size And Forecast, By Age Group
9.2.6.8. Canada Market Size And Forecast, By Route of Administration
9.2.6.9. Mexico Market Size And Forecast, By Vaccine Type
9.2.6.10. Mexico Market Size And Forecast, By Technology
9.2.6.11. Mexico Market Size And Forecast, By Age Group
9.2.6.12. Mexico Market Size And Forecast, By Route of Administration
9.3. Europe
9.3.1. Key Market Trends And Opportunities
9.3.2. Market Size And Forecast, By Vaccine Type
9.3.3. Market Size And Forecast, By Technology
9.3.4. Market Size And Forecast, By Age Group
9.3.5. Market Size And Forecast, By Route of Administration
9.3.6. Market Size And Forecast, By Country
9.3.6.1. Germany Market Size And Forecast, By Vaccine Type
9.3.6.2. Germany Market Size And Forecast, By Technology
9.3.6.3. Germany Market Size And Forecast, By Age Group
9.3.6.4. Germany Market Size And Forecast, By Route of Administration
9.3.6.5. France Market Size And Forecast, By Vaccine Type
9.3.6.6. France Market Size And Forecast, By Technology
9.3.6.7. France Market Size And Forecast, By Age Group
9.3.6.8. France Market Size And Forecast, By Route of Administration
9.3.6.9. Uk Market Size And Forecast, By Vaccine Type
9.3.6.10. Uk Market Size And Forecast, By Technology
9.3.6.11. Uk Market Size And Forecast, By Age Group
9.3.6.12. Uk Market Size And Forecast, By Route of Administration
9.3.6.13. Italy Market Size And Forecast, By Vaccine Type
9.3.6.14. Italy Market Size And Forecast, By Technology
9.3.6.15. Italy Market Size And Forecast, By Age Group
9.3.6.16. Italy Market Size And Forecast, By Route of Administration
9.3.6.17. Spain Market Size And Forecast, By Vaccine Type
9.3.6.18. Spain Market Size And Forecast, By Technology
9.3.6.19. Spain Market Size And Forecast, By Age Group
9.3.6.20. Spain Market Size And Forecast, By Route of Administration
9.3.6.21. Rest of Europe Market Size And Forecast, By Vaccine Type
9.3.6.22. Rest of Europe Market Size And Forecast, By Technology
9.3.6.23. Rest of Europe Market Size And Forecast, By Age Group
9.3.6.24. Rest of Europe Market Size And Forecast, By Route of Administration
9.4. Asia-Pacific
9.4.1. Key Market Trends And Opportunities
9.4.2. Market Size And Forecast, By Vaccine Type
9.4.3. Market Size And Forecast, By Technology
9.4.4. Market Size And Forecast, By Age Group
9.4.5. Market Size And Forecast, By Route of Administration
9.4.6. Market Size And Forecast, By Country
9.4.6.1. Japan Market Size And Forecast, By Vaccine Type
9.4.6.2. Japan Market Size And Forecast, By Technology
9.4.6.3. Japan Market Size And Forecast, By Age Group
9.4.6.4. Japan Market Size And Forecast, By Route of Administration
9.4.6.5. China Market Size And Forecast, By Vaccine Type
9.4.6.6. China Market Size And Forecast, By Technology
9.4.6.7. China Market Size And Forecast, By Age Group
9.4.6.8. China Market Size And Forecast, By Route of Administration
9.4.6.9. India Market Size And Forecast, By Vaccine Type
9.4.6.10. India Market Size And Forecast, By Technology
9.4.6.11. India Market Size And Forecast, By Age Group
9.4.6.12. India Market Size And Forecast, By Route of Administration
9.4.6.13. Australia Market Size And Forecast, By Vaccine Type
9.4.6.14. Australia Market Size And Forecast, By Technology
9.4.6.15. Australia Market Size And Forecast, By Age Group
9.4.6.16. Australia Market Size And Forecast, By Route of Administration
9.4.6.17. South Korea Market Size And Forecast, By Vaccine Type
9.4.6.18. South Korea Market Size And Forecast, By Technology
9.4.6.19. South Korea Market Size And Forecast, By Age Group
9.4.6.20. South Korea Market Size And Forecast, By Route of Administration
9.4.6.21. Rest of Asia-Pacific Market Size And Forecast, By Vaccine Type
9.4.6.22. Rest of Asia-Pacific Market Size And Forecast, By Technology
9.4.6.23. Rest of Asia-Pacific Market Size And Forecast, By Age Group
9.4.6.24. Rest of Asia-Pacific Market Size And Forecast, By Route of Administration
9.5. Lamea
9.5.1. Key Market Trends And Opportunities
9.5.2. Market Size And Forecast, By Vaccine Type
9.5.3. Market Size And Forecast, By Technology
9.5.4. Market Size And Forecast, By Age Group
9.5.5. Market Size And Forecast, By Route of Administration
9.5.6. Market Size And Forecast, By Country
9.5.6.1. Brazil Market Size And Forecast, By Vaccine Type
9.5.6.2. Brazil Market Size And Forecast, By Technology
9.5.6.3. Brazil Market Size And Forecast, By Age Group
9.5.6.4. Brazil Market Size And Forecast, By Route of Administration
9.5.6.5. Saudi Market Size And Forecast, By Vaccine Type
9.5.6.6. Saudi Market Size And Forecast, By Technology
9.5.6.7. Saudi Market Size And Forecast, By Age Group
9.5.6.8. Saudi Market Size And Forecast, By Route of Administration
9.5.6.9. South Africa Market Size And Forecast, By Vaccine Type
9.5.6.10. South Africa Market Size And Forecast, By Technology
9.5.6.11. South Africa Market Size And Forecast, By Age Group
9.5.6.12. South Africa Market Size And Forecast, By Route of Administration
9.5.6.13. Rest of Lamea Market Size And Forecast, By Vaccine Type
9.5.6.14. Rest of Lamea Market Size And Forecast, By Technology
9.5.6.15. Rest of Lamea Market Size And Forecast, By Age Group
9.5.6.16. Rest of Lamea Market Size And Forecast, By Route of Administration
CHAPTER 10: COMPANY PROFILES
10.1. Astrazeneca Plc (Astrazeneca)
10.1.1. Company Overview
10.1.2. Company Snapshot
10.1.3. Operating Business Segments
10.1.4. Product Portfolio
10.1.5. Business Performance
10.2. Biodiem
10.2.1. Company Overview
10.2.2. Company Snapshot
10.2.3. Operating Business Segments
10.2.4. Product Portfolio
10.2.5. Business Performance
10.3. Csl Limited (Seqirus Gmbh)
10.3.1. Company Overview
10.3.2. Company Snapshot
10.3.3. Operating Business Segments
10.3.4. Product Portfolio
10.3.5. Business Performance
10.3.6. Key Strategic Moves And Developments
10.4. Emergent Biosolutions
10.4.1. Company Overview
10.4.2. Company Snapshot
10.4.3. Operating Business Segments
10.4.4. Product Portfolio
10.4.5. Business Performance
10.5. F. Hoffmann-La Roche Ltd.
10.5.1. Company Overview
10.5.2. Company Snapshot
10.5.3. Operating Business Segments
10.5.4. Product Portfolio
10.5.5. Business Performance
10.6. Gamma Vaccines Pty Ltd.
10.6.1. Company Overview
10.6.2. Company Snapshot
10.6.3. Operating Business Segments
10.6.4. Product Portfolio
10.7. Glaxosmithkline Plc
10.7.1. Company Overview
10.7.2. Company Snapshot
10.7.3. Operating Business Segments
10.7.4. Product Portfolio
10.7.5. Business Performance
10.7.6. Key Strategic Moves And Developments
10.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
10.8.1. Company Overview
10.8.2. Company Snapshot
10.8.3. Operating Business Segments
10.8.4. Product Portfolio
10.8.5. Business Performance
10.9. Novartis Ag
10.9.1. Company Overview
10.9.2. Company Snapshot
10.9.3. Operating Business Segments
10.9.4. Product Portfolio
10.9.5. Business Performance
10.10. Pfizer, Inc.
10.10.1. Company Overview
10.10.2. Company Snapshot
10.10.3. Operating Business Segments
10.10.4. Product Portfolio
10.10.5. Business Performance
10.10.6. Key Strategic Moves And Developments
10.11. Sanofi
10.11.1. Company Overview
10.11.2. Company Snapshot
10.11.3. Operating Business Segments
10.11.4. Product Portfolio
10.11.5. Business Performance
10.12. Sinovac Biotech Ltd.
10.12.1. Company Overview
10.12.2. Company Snapshot
10.12.3. Operating Business Segments
10.12.4. Product Portfolio
10.12.5. Business Performance
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key Findings of The Study
2.2. Cxo Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter'S Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. High Prevalence of Influenza
3.4.1.2. Increase In Government Focus On Immunization Programs
3.4.1.3. Emerging Vaccines
3.4.1.4. Technological Progress In Vaccine Administration
3.4.2. Restraints
3.4.2.1. Longer Timelines And Implementation of Stringent Regulations
3.4.2.2. High Costs Associated With The Development of Vaccines
3.4.3. Opportunity
3.4.3.1. High Growth Prospects In Emerging Markets
CHAPTER 4: INFLUENZA VACCINE MARKET, BY VACCINE TYPE
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Quadrivalent
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Trivalent
4.3.1. Key Market Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
CHAPTER 5: INFLUENZA VACCINE MARKET, BY TYPE
5.1. Overview
5.2. Seasonal Influenza Vaccine
5.3. Pandemic Influenza Vaccine
CHAPTER 6: INFLUENZA VACCINE MARKET, BY TECHNOLOGY
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Egg-Based
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Cell Culture
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
CHAPTER 7: INFLUENZA VACCINE MARKET, BY AGE GROUP
7.1. Overview
7.1.1. Market Size And Forecast
7.2. Pediatric
7.2.1. Market Size And Forecast, By Region
7.2.2. Market Analysis, By Country
7.3. Adult
7.3.1. Market Size And Forecast, By Region
7.3.2. Market Analysis, By Country
CHAPTER 8: INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION
8.1. Overview
8.1.1. Market Size And Forecast
8.2. Injection
8.2.1. Market Size And Forecast
8.2.2. Market Analysis, By Country
8.3. Nasal Spray
8.3.1. Market Size And Forecast
8.3.2. Market Analysis, By Country
CHAPTER 9: GLOBAL INFLUENZA VACCINE MARKET, BY REGION
9.1. Overview
9.1.1. Market Size And Forecast
9.2. North America
9.2.1. Key Market Trends And Opportunities
9.2.2. Market Size And Forecast, By Vaccine Type
9.2.3. Market Size And Forecast, By Technology
9.2.4. Market Size And Forecast, By Age Group
9.2.5. Market Size And Forecast, By Route of Administration
9.2.6. Market Size And Forecast, By Country
9.2.6.1. U.S. Market Size And Forecast, By Vaccine Type
9.2.6.2. U.S. Market Size And Forecast, By Technology
9.2.6.3. U.S. Market Size And Forecast, By Age Group
9.2.6.4. U.S. Market Size And Forecast, By Route of Administration
9.2.6.5. Canada Market Size And Forecast, By Vaccine Type
9.2.6.6. Canada Market Size And Forecast, By Technology
9.2.6.7. Canada Market Size And Forecast, By Age Group
9.2.6.8. Canada Market Size And Forecast, By Route of Administration
9.2.6.9. Mexico Market Size And Forecast, By Vaccine Type
9.2.6.10. Mexico Market Size And Forecast, By Technology
9.2.6.11. Mexico Market Size And Forecast, By Age Group
9.2.6.12. Mexico Market Size And Forecast, By Route of Administration
9.3. Europe
9.3.1. Key Market Trends And Opportunities
9.3.2. Market Size And Forecast, By Vaccine Type
9.3.3. Market Size And Forecast, By Technology
9.3.4. Market Size And Forecast, By Age Group
9.3.5. Market Size And Forecast, By Route of Administration
9.3.6. Market Size And Forecast, By Country
9.3.6.1. Germany Market Size And Forecast, By Vaccine Type
9.3.6.2. Germany Market Size And Forecast, By Technology
9.3.6.3. Germany Market Size And Forecast, By Age Group
9.3.6.4. Germany Market Size And Forecast, By Route of Administration
9.3.6.5. France Market Size And Forecast, By Vaccine Type
9.3.6.6. France Market Size And Forecast, By Technology
9.3.6.7. France Market Size And Forecast, By Age Group
9.3.6.8. France Market Size And Forecast, By Route of Administration
9.3.6.9. Uk Market Size And Forecast, By Vaccine Type
9.3.6.10. Uk Market Size And Forecast, By Technology
9.3.6.11. Uk Market Size And Forecast, By Age Group
9.3.6.12. Uk Market Size And Forecast, By Route of Administration
9.3.6.13. Italy Market Size And Forecast, By Vaccine Type
9.3.6.14. Italy Market Size And Forecast, By Technology
9.3.6.15. Italy Market Size And Forecast, By Age Group
9.3.6.16. Italy Market Size And Forecast, By Route of Administration
9.3.6.17. Spain Market Size And Forecast, By Vaccine Type
9.3.6.18. Spain Market Size And Forecast, By Technology
9.3.6.19. Spain Market Size And Forecast, By Age Group
9.3.6.20. Spain Market Size And Forecast, By Route of Administration
9.3.6.21. Rest of Europe Market Size And Forecast, By Vaccine Type
9.3.6.22. Rest of Europe Market Size And Forecast, By Technology
9.3.6.23. Rest of Europe Market Size And Forecast, By Age Group
9.3.6.24. Rest of Europe Market Size And Forecast, By Route of Administration
9.4. Asia-Pacific
9.4.1. Key Market Trends And Opportunities
9.4.2. Market Size And Forecast, By Vaccine Type
9.4.3. Market Size And Forecast, By Technology
9.4.4. Market Size And Forecast, By Age Group
9.4.5. Market Size And Forecast, By Route of Administration
9.4.6. Market Size And Forecast, By Country
9.4.6.1. Japan Market Size And Forecast, By Vaccine Type
9.4.6.2. Japan Market Size And Forecast, By Technology
9.4.6.3. Japan Market Size And Forecast, By Age Group
9.4.6.4. Japan Market Size And Forecast, By Route of Administration
9.4.6.5. China Market Size And Forecast, By Vaccine Type
9.4.6.6. China Market Size And Forecast, By Technology
9.4.6.7. China Market Size And Forecast, By Age Group
9.4.6.8. China Market Size And Forecast, By Route of Administration
9.4.6.9. India Market Size And Forecast, By Vaccine Type
9.4.6.10. India Market Size And Forecast, By Technology
9.4.6.11. India Market Size And Forecast, By Age Group
9.4.6.12. India Market Size And Forecast, By Route of Administration
9.4.6.13. Australia Market Size And Forecast, By Vaccine Type
9.4.6.14. Australia Market Size And Forecast, By Technology
9.4.6.15. Australia Market Size And Forecast, By Age Group
9.4.6.16. Australia Market Size And Forecast, By Route of Administration
9.4.6.17. South Korea Market Size And Forecast, By Vaccine Type
9.4.6.18. South Korea Market Size And Forecast, By Technology
9.4.6.19. South Korea Market Size And Forecast, By Age Group
9.4.6.20. South Korea Market Size And Forecast, By Route of Administration
9.4.6.21. Rest of Asia-Pacific Market Size And Forecast, By Vaccine Type
9.4.6.22. Rest of Asia-Pacific Market Size And Forecast, By Technology
9.4.6.23. Rest of Asia-Pacific Market Size And Forecast, By Age Group
9.4.6.24. Rest of Asia-Pacific Market Size And Forecast, By Route of Administration
9.5. Lamea
9.5.1. Key Market Trends And Opportunities
9.5.2. Market Size And Forecast, By Vaccine Type
9.5.3. Market Size And Forecast, By Technology
9.5.4. Market Size And Forecast, By Age Group
9.5.5. Market Size And Forecast, By Route of Administration
9.5.6. Market Size And Forecast, By Country
9.5.6.1. Brazil Market Size And Forecast, By Vaccine Type
9.5.6.2. Brazil Market Size And Forecast, By Technology
9.5.6.3. Brazil Market Size And Forecast, By Age Group
9.5.6.4. Brazil Market Size And Forecast, By Route of Administration
9.5.6.5. Saudi Market Size And Forecast, By Vaccine Type
9.5.6.6. Saudi Market Size And Forecast, By Technology
9.5.6.7. Saudi Market Size And Forecast, By Age Group
9.5.6.8. Saudi Market Size And Forecast, By Route of Administration
9.5.6.9. South Africa Market Size And Forecast, By Vaccine Type
9.5.6.10. South Africa Market Size And Forecast, By Technology
9.5.6.11. South Africa Market Size And Forecast, By Age Group
9.5.6.12. South Africa Market Size And Forecast, By Route of Administration
9.5.6.13. Rest of Lamea Market Size And Forecast, By Vaccine Type
9.5.6.14. Rest of Lamea Market Size And Forecast, By Technology
9.5.6.15. Rest of Lamea Market Size And Forecast, By Age Group
9.5.6.16. Rest of Lamea Market Size And Forecast, By Route of Administration
CHAPTER 10: COMPANY PROFILES
10.1. Astrazeneca Plc (Astrazeneca)
10.1.1. Company Overview
10.1.2. Company Snapshot
10.1.3. Operating Business Segments
10.1.4. Product Portfolio
10.1.5. Business Performance
10.2. Biodiem
10.2.1. Company Overview
10.2.2. Company Snapshot
10.2.3. Operating Business Segments
10.2.4. Product Portfolio
10.2.5. Business Performance
10.3. Csl Limited (Seqirus Gmbh)
10.3.1. Company Overview
10.3.2. Company Snapshot
10.3.3. Operating Business Segments
10.3.4. Product Portfolio
10.3.5. Business Performance
10.3.6. Key Strategic Moves And Developments
10.4. Emergent Biosolutions
10.4.1. Company Overview
10.4.2. Company Snapshot
10.4.3. Operating Business Segments
10.4.4. Product Portfolio
10.4.5. Business Performance
10.5. F. Hoffmann-La Roche Ltd.
10.5.1. Company Overview
10.5.2. Company Snapshot
10.5.3. Operating Business Segments
10.5.4. Product Portfolio
10.5.5. Business Performance
10.6. Gamma Vaccines Pty Ltd.
10.6.1. Company Overview
10.6.2. Company Snapshot
10.6.3. Operating Business Segments
10.6.4. Product Portfolio
10.7. Glaxosmithkline Plc
10.7.1. Company Overview
10.7.2. Company Snapshot
10.7.3. Operating Business Segments
10.7.4. Product Portfolio
10.7.5. Business Performance
10.7.6. Key Strategic Moves And Developments
10.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
10.8.1. Company Overview
10.8.2. Company Snapshot
10.8.3. Operating Business Segments
10.8.4. Product Portfolio
10.8.5. Business Performance
10.9. Novartis Ag
10.9.1. Company Overview
10.9.2. Company Snapshot
10.9.3. Operating Business Segments
10.9.4. Product Portfolio
10.9.5. Business Performance
10.10. Pfizer, Inc.
10.10.1. Company Overview
10.10.2. Company Snapshot
10.10.3. Operating Business Segments
10.10.4. Product Portfolio
10.10.5. Business Performance
10.10.6. Key Strategic Moves And Developments
10.11. Sanofi
10.11.1. Company Overview
10.11.2. Company Snapshot
10.11.3. Operating Business Segments
10.11.4. Product Portfolio
10.11.5. Business Performance
10.12. Sinovac Biotech Ltd.
10.12.1. Company Overview
10.12.2. Company Snapshot
10.12.3. Operating Business Segments
10.12.4. Product Portfolio
10.12.5. Business Performance
LIST OF TABLES
Table 01. Global Influenza Vaccine Market, By Vaccine Type, 2018–2026, ($Million)
Table 02. Influenza Vaccine Market For Quadrivalent, By Region, 2018–2026, ($Million)
Table 03. Influenza Vaccine Market For Trivalent, By Region, 2018–2026, ($Million)
Table 04. Global Influenza Vaccine Market, By Technology, 2018–2026 ($Million)
Table 05. Egg-Based Influenza Vaccine Market, By Region, 2018–2026 ($Million)
Table 06. Cell Culture Influenza Vaccine Market, By Region, 2018–2026 ($Million)
Table 07. Global Influenza Vaccine Market, By Age Group, 2018–2026, ($Million)
Table 08. Influenza Vaccine Market For Pediatric Age Group, By Region, 2018–2026, ($Million)
Table 09. Influenza Vaccine Market For Adult Age Group, By Region, 2018–2026, ($Million)
Table 10. Global Influenza Vaccine Market, By Route of Administration, 2018–2026, ($Million)
Table 11. Influenza Vaccine Market For Injection, By Region, 2018–2026, ($Million)
Table 12. Influenza Vaccine Market For Nasal Spray, By Region, 2018–2026, ($Million)
Table 13. Global Influenza Vaccine Market By Region, 2018-2026, ($Million)
Table 14. Canada Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 15. Canada Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 16. Canada Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 17. Canada Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 18. North America Influenza Vaccine Market By Country, 2018-2026, ($Million)
Table 19. U.S. Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 20. U.S. Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 21. U.S. Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 22. U.S. Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 23. Canada Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 24. Canada Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 25. Canada Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 26. Canada Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 27. Mexico Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 28. Mexico Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 29. Mexico Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 30. Mexico Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 31. Europe Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 32. Europe Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 33. Europe Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 34. Europe Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 35. Europe Influenza Vaccine Market By Country, 2018-2026, ($Million)
Table 36. Germany Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 37. Germany Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 38. Germany Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 39. Germany Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 40. France Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 41. France Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 42. France Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 43. France Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 44. Uk Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 45. Uk Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 46. Uk Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 47. Uk Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 48. Italy Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 49. Italy Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 50. Italy Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 51. Italy Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 52. Spain Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 53. Spain Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 54. Spain Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 55. Spain Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 56. Rest of Europe Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 57. Rest of Europe Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 58. Rest of Europe Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 59. Rest of Europe Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 60. Asia-Pacific Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 61. Asia-Pacific Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 62. Asia-Pacific Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 63. Asia-Pacific Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 64. Asia-Pacific Influenza Vaccine Market By Country, 2018-2026, ($Million)
Table 65. Japan Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 66. Japan Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 67. Japan Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 68. Japan Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 69. China Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 70. China Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 71. China Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 72. China Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 73. India Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 74. India Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 75. India Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 76. India Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 77. Australia Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 78. Australia Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 79. Australia Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 80. Australia Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 81. South Korea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 82. South Korea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 83. South Korea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 84. South Korea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 85. Rest of Asia-Pacific Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 86. Rest of Asia-Pacific Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 87. Rest of Asia-Pacific Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 88. Rest of Asia-Pacific Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 89. Lamea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 90. Lamea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 91. Lamea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 92. Lamea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 93. Lamea Influenza Vaccine Market By Country, 2018-2026, ($Million)
Table 94. Brazil Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 95. Brazil Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 96. Brazil Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 97. Brazil Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 98. Saudi Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 99. Saudi Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 100. Saudi Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 101. Saudi Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 102. South Africa Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 103. South Africa Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 104. South Africa Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 105. South Africa Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 106. Rest of Lamea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 107. Rest of Lamea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 108. Rest of Lamea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 109. Rest of Lamea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 110. Astrazeneca: Company Snapshot
Table 111. Astrazeneca: Operating Segments
Table 112. Astrazeneca: Product Portfolio
Table 113. Biodiem: Company Snapshot
Table 114. Biodiem: Operating Segments
Table 115. Biodiem: Product Portfolio
Table 116. Csl Limited: Company Snapshot
Table 117. Csl Limited: Operating Segments
Table 118. Csl Limited: Product Portfolio
Table 119. Emergent Biosolutions: Company Snapshot
Table 120. Emergent Biosolutions: Operating Segments
Table 121. Emergent Biosolutions: Product Portfolio
Table 122. Roche: Company Snapshot
Table 123. Roche: Operating Segments
Table 124. Roche: Product Portfolio
Table 125. Gamma Vaccines: Company Snapshot
Table 126. Gamma Vaccines: Operating Segments
Table 127. Gamma Vaccines: Product Type Portfolio
Table 128. Gsk: Company Snapshot
Table 129. Gsk: Operating Segments
Table 130. Gsk: Product Portfolio
Table 131. Merck.: Company Snapshot
Table 132. Merck: Operating Segments
Table 133. Merck: Product Type Portfolio
Table 134. Novartis: Company Snapshot
Table 135. Novartis: Operating Segments
Table 136. Novartis: Product Type Portfolio
Table 137. Pfizer: Company Snapshot
Table 138. Pfizer: Operating Segments
Table 139. Pfizer: Product Type Portfolio
Table 140. Sanofi: Company Snapshot
Table 141. Sanofi: Operating Segments
Table 142. Sanofi: Product Type Portfolio
Table 143. Sinovac Biotech: Company Snapshot
Table 144. Sinovac Biotech: Operating Segments
Table 145. Sinovac Biotech: Product Type Portfolio
Table 01. Global Influenza Vaccine Market, By Vaccine Type, 2018–2026, ($Million)
Table 02. Influenza Vaccine Market For Quadrivalent, By Region, 2018–2026, ($Million)
Table 03. Influenza Vaccine Market For Trivalent, By Region, 2018–2026, ($Million)
Table 04. Global Influenza Vaccine Market, By Technology, 2018–2026 ($Million)
Table 05. Egg-Based Influenza Vaccine Market, By Region, 2018–2026 ($Million)
Table 06. Cell Culture Influenza Vaccine Market, By Region, 2018–2026 ($Million)
Table 07. Global Influenza Vaccine Market, By Age Group, 2018–2026, ($Million)
Table 08. Influenza Vaccine Market For Pediatric Age Group, By Region, 2018–2026, ($Million)
Table 09. Influenza Vaccine Market For Adult Age Group, By Region, 2018–2026, ($Million)
Table 10. Global Influenza Vaccine Market, By Route of Administration, 2018–2026, ($Million)
Table 11. Influenza Vaccine Market For Injection, By Region, 2018–2026, ($Million)
Table 12. Influenza Vaccine Market For Nasal Spray, By Region, 2018–2026, ($Million)
Table 13. Global Influenza Vaccine Market By Region, 2018-2026, ($Million)
Table 14. Canada Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 15. Canada Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 16. Canada Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 17. Canada Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 18. North America Influenza Vaccine Market By Country, 2018-2026, ($Million)
Table 19. U.S. Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 20. U.S. Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 21. U.S. Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 22. U.S. Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 23. Canada Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 24. Canada Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 25. Canada Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 26. Canada Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 27. Mexico Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 28. Mexico Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 29. Mexico Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 30. Mexico Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 31. Europe Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 32. Europe Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 33. Europe Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 34. Europe Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 35. Europe Influenza Vaccine Market By Country, 2018-2026, ($Million)
Table 36. Germany Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 37. Germany Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 38. Germany Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 39. Germany Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 40. France Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 41. France Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 42. France Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 43. France Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 44. Uk Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 45. Uk Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 46. Uk Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 47. Uk Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 48. Italy Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 49. Italy Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 50. Italy Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 51. Italy Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 52. Spain Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 53. Spain Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 54. Spain Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 55. Spain Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 56. Rest of Europe Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 57. Rest of Europe Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 58. Rest of Europe Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 59. Rest of Europe Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 60. Asia-Pacific Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 61. Asia-Pacific Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 62. Asia-Pacific Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 63. Asia-Pacific Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 64. Asia-Pacific Influenza Vaccine Market By Country, 2018-2026, ($Million)
Table 65. Japan Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 66. Japan Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 67. Japan Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 68. Japan Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 69. China Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 70. China Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 71. China Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 72. China Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 73. India Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 74. India Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 75. India Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 76. India Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 77. Australia Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 78. Australia Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 79. Australia Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 80. Australia Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 81. South Korea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 82. South Korea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 83. South Korea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 84. South Korea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 85. Rest of Asia-Pacific Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 86. Rest of Asia-Pacific Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 87. Rest of Asia-Pacific Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 88. Rest of Asia-Pacific Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 89. Lamea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 90. Lamea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 91. Lamea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 92. Lamea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 93. Lamea Influenza Vaccine Market By Country, 2018-2026, ($Million)
Table 94. Brazil Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 95. Brazil Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 96. Brazil Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 97. Brazil Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 98. Saudi Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 99. Saudi Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 100. Saudi Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 101. Saudi Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 102. South Africa Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 103. South Africa Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 104. South Africa Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 105. South Africa Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 106. Rest of Lamea Influenza Vaccine Market By Vaccine Type, 2018-2026, ($Million)
Table 107. Rest of Lamea Influenza Vaccine Market By Technology, 2018-2026, ($Million)
Table 108. Rest of Lamea Influenza Vaccine Market By Age Group, 2018-2026, ($Million)
Table 109. Rest of Lamea Influenza Vaccine Market By Route of Administration, 2018-2026, ($Million)
Table 110. Astrazeneca: Company Snapshot
Table 111. Astrazeneca: Operating Segments
Table 112. Astrazeneca: Product Portfolio
Table 113. Biodiem: Company Snapshot
Table 114. Biodiem: Operating Segments
Table 115. Biodiem: Product Portfolio
Table 116. Csl Limited: Company Snapshot
Table 117. Csl Limited: Operating Segments
Table 118. Csl Limited: Product Portfolio
Table 119. Emergent Biosolutions: Company Snapshot
Table 120. Emergent Biosolutions: Operating Segments
Table 121. Emergent Biosolutions: Product Portfolio
Table 122. Roche: Company Snapshot
Table 123. Roche: Operating Segments
Table 124. Roche: Product Portfolio
Table 125. Gamma Vaccines: Company Snapshot
Table 126. Gamma Vaccines: Operating Segments
Table 127. Gamma Vaccines: Product Type Portfolio
Table 128. Gsk: Company Snapshot
Table 129. Gsk: Operating Segments
Table 130. Gsk: Product Portfolio
Table 131. Merck.: Company Snapshot
Table 132. Merck: Operating Segments
Table 133. Merck: Product Type Portfolio
Table 134. Novartis: Company Snapshot
Table 135. Novartis: Operating Segments
Table 136. Novartis: Product Type Portfolio
Table 137. Pfizer: Company Snapshot
Table 138. Pfizer: Operating Segments
Table 139. Pfizer: Product Type Portfolio
Table 140. Sanofi: Company Snapshot
Table 141. Sanofi: Operating Segments
Table 142. Sanofi: Product Type Portfolio
Table 143. Sinovac Biotech: Company Snapshot
Table 144. Sinovac Biotech: Operating Segments
Table 145. Sinovac Biotech: Product Type Portfolio
LIST OF FIGURES
Figure 01. Influenza Vaccine Market Segmentation
Figure 02. Top Investment Pockets
Figure 03. Top Winning Strategies, By Year, 2016–2019*
Figure 04. Top Winning Strategies, By Development, 2016–2019* (%)
Figure 05. Top Winning Strategies, By Company, 2016–2019*
Figure 06. Low-Moderate Bargaining Power of Suppliers
Figure 07. High Bargaining Power of Buyers
Figure 08. Moderate Threat of New Entrants
Figure 09. Moderate Threat of Substitution
Figure 10. High Intensity of Competitive Rivalry
Figure 11. Top Impacting Factors
Figure 12. Comparative Share Analysis of Influenza Vaccine For Quadrivalent, By Country, 2018 & 2026 (%)
Figure 13. Comparative Share Analysis of Influenza Vaccine Market For Trivalent, By Country, 2018 & 2026 (%)
Figure 14. Comparative Share Analysis of Egg-Based Influenza Vaccine, By Country, 2018 & 2026 (%)
Figure 15. Comparative Share Analysis of Cell Culture Influenza Vaccine Market, By Country, 2018 & 2026 (%)
Figure 16. Comparative Share Analysis of Influenza Vaccine For Pediatric Age Group, By Country, 2018 & 2026 (%)
Figure 17. Comparative Share Analysis of Influenza Vaccine Market For Adult Age Group, By Country, 2018 & 2026 (%)
Figure 18. Comparative Share Analysis of Influenza Vaccine For Injection, By Country, 2018 & 2026 (%)
Figure 19. Comparative Share Analysis of Influenza Vaccine Market For Nasal Spray, By Country, 2018 & 2026 (%)
Figure 20. Astrazeneca: Revenue, 2016–2018 ($Million)
Figure 21. Astrazeneca: Revenue Share By Segment, 2018 (%)
Figure 22. Astrazeneca: Revenue Share By Region, 2018 (%)
Figure 23. Biodiem: Revenue, 2016–2018 ($Million)
Figure 24. Csl Limited: Revenue, 2016–2018 ($Million)
Figure 25. Csl Limited: Revenue Share By Segment, 2018 (%)
Figure 26. Csl Limited: Revenue Share By Region, 2018 (%)
Figure 27. Emergent Biosolutions: Revenue, 2016–2018 ($Million)
Figure 28. Emergent Biosolutions: Revenue Share By Product, 2018 (%)
Figure 29. Emergent Biosolutions: Revenue Share By Region, 2018 (%)
Figure 30. Roche: Revenue, 2016–2018 ($Million)
Figure 31. Roche: Revenue Share By Segment, 2018 (%)
Figure 32. Roche: Revenue Share By Region, 2018 (%)
Figure 33. Gsk: Revenue, 2016–2018 ($Million)
Figure 34. Gsk: Revenue Share By Segment, 2018 (%)
Figure 35. Gsk: Revenue Share By Region, 2018 (%)
Figure 36. Merck: Revenue, 2016–2018 ($Million)
Figure 37. Merck: Revenue Share By Segment, 2018 (%)
Figure 38. Merck: Revenue Share By Region, 2018 (%)
Figure 39. Novartis: Revenue, 2016–2018 ($Million)
Figure 40. Novartis: Revenue Share By Segment, 2018 (%)
Figure 41. Novartis: Revenue Share By Region, 2018 (%)
Figure 42. Pfizer: Revenue, 2016–2018 ($Million)
Figure 43. Pfizer: Revenue Share By Segment, 2018 (%)
Figure 44. Pfizer: Revenue Share By Region, 2018 (%)
Figure 45. Sanofi: Revenue, 2016–2018 ($Million)
Figure 46. Sanofi: Revenue Share By Segment, 2018 (%)
Figure 47. Sanofi: Revenue Share By Region, 2018 (%)
Figure 48. Sinovac Biotech: Revenue, 2016–2018 ($Million)
Figure 49. Sinovac Biotech: Revenue Share By Product, 2018 (%)
Figure 50. Sinovac Biotech: Revenue Share By Region, 2018 (%)
Figure 01. Influenza Vaccine Market Segmentation
Figure 02. Top Investment Pockets
Figure 03. Top Winning Strategies, By Year, 2016–2019*
Figure 04. Top Winning Strategies, By Development, 2016–2019* (%)
Figure 05. Top Winning Strategies, By Company, 2016–2019*
Figure 06. Low-Moderate Bargaining Power of Suppliers
Figure 07. High Bargaining Power of Buyers
Figure 08. Moderate Threat of New Entrants
Figure 09. Moderate Threat of Substitution
Figure 10. High Intensity of Competitive Rivalry
Figure 11. Top Impacting Factors
Figure 12. Comparative Share Analysis of Influenza Vaccine For Quadrivalent, By Country, 2018 & 2026 (%)
Figure 13. Comparative Share Analysis of Influenza Vaccine Market For Trivalent, By Country, 2018 & 2026 (%)
Figure 14. Comparative Share Analysis of Egg-Based Influenza Vaccine, By Country, 2018 & 2026 (%)
Figure 15. Comparative Share Analysis of Cell Culture Influenza Vaccine Market, By Country, 2018 & 2026 (%)
Figure 16. Comparative Share Analysis of Influenza Vaccine For Pediatric Age Group, By Country, 2018 & 2026 (%)
Figure 17. Comparative Share Analysis of Influenza Vaccine Market For Adult Age Group, By Country, 2018 & 2026 (%)
Figure 18. Comparative Share Analysis of Influenza Vaccine For Injection, By Country, 2018 & 2026 (%)
Figure 19. Comparative Share Analysis of Influenza Vaccine Market For Nasal Spray, By Country, 2018 & 2026 (%)
Figure 20. Astrazeneca: Revenue, 2016–2018 ($Million)
Figure 21. Astrazeneca: Revenue Share By Segment, 2018 (%)
Figure 22. Astrazeneca: Revenue Share By Region, 2018 (%)
Figure 23. Biodiem: Revenue, 2016–2018 ($Million)
Figure 24. Csl Limited: Revenue, 2016–2018 ($Million)
Figure 25. Csl Limited: Revenue Share By Segment, 2018 (%)
Figure 26. Csl Limited: Revenue Share By Region, 2018 (%)
Figure 27. Emergent Biosolutions: Revenue, 2016–2018 ($Million)
Figure 28. Emergent Biosolutions: Revenue Share By Product, 2018 (%)
Figure 29. Emergent Biosolutions: Revenue Share By Region, 2018 (%)
Figure 30. Roche: Revenue, 2016–2018 ($Million)
Figure 31. Roche: Revenue Share By Segment, 2018 (%)
Figure 32. Roche: Revenue Share By Region, 2018 (%)
Figure 33. Gsk: Revenue, 2016–2018 ($Million)
Figure 34. Gsk: Revenue Share By Segment, 2018 (%)
Figure 35. Gsk: Revenue Share By Region, 2018 (%)
Figure 36. Merck: Revenue, 2016–2018 ($Million)
Figure 37. Merck: Revenue Share By Segment, 2018 (%)
Figure 38. Merck: Revenue Share By Region, 2018 (%)
Figure 39. Novartis: Revenue, 2016–2018 ($Million)
Figure 40. Novartis: Revenue Share By Segment, 2018 (%)
Figure 41. Novartis: Revenue Share By Region, 2018 (%)
Figure 42. Pfizer: Revenue, 2016–2018 ($Million)
Figure 43. Pfizer: Revenue Share By Segment, 2018 (%)
Figure 44. Pfizer: Revenue Share By Region, 2018 (%)
Figure 45. Sanofi: Revenue, 2016–2018 ($Million)
Figure 46. Sanofi: Revenue Share By Segment, 2018 (%)
Figure 47. Sanofi: Revenue Share By Region, 2018 (%)
Figure 48. Sinovac Biotech: Revenue, 2016–2018 ($Million)
Figure 49. Sinovac Biotech: Revenue Share By Product, 2018 (%)
Figure 50. Sinovac Biotech: Revenue Share By Region, 2018 (%)
